Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Apr. 01, 2022
Cash flows from operating activities:
Net income	$ 43.8	$ 74.9
Noncash items:
Depreciation	8.5	7.8
Amortization	27.9	23.5
Allowance for credit losses	2.0	1.7
Stock-based compensation expense	15.0	7.5
Gain on sale of property, plant and equipment	0.0	(6.0)
Restructuring charges	0.1	(1.9)
Impairment charges	0.3	3.9
Amortization of right-of-use assets	6.5	6.4
Amortization of debt discount and issuance costs	1.0	1.0
Change in trade accounts receivable	(8.5)	(16.2)
Change in inventories	(7.1)	(20.3)
Change in trade accounts payable	(38.1)	(2.5)
Change in prepaid expenses and other assets	1.3	(16.8)
Change in accrued expenses and other liabilities	(41.3)	(51.5)
Change in operating lease liabilities	(8.3)	(8.0)
Net cash provided by operating activities	3.1	3.5
Cash flows from investing activities:
Payments for additions to property, plant and equipment	(17.5)	(19.8)
Proceeds from sale of KaVo treatment unit and instrument business, net	0.0	30.0
All other investing activities, net	(4.5)	(5.1)
Net cash (used in) provided by investing activities	(22.0)	5.1
Cash flows from financing activities:
Proceeds from borrowing	0.0	0.3
Repayment of borrowing	0.0	(0.5)
Proceeds from stock option exercises	4.6	13.1
Tax withholding payment related to net settlement of equity awards	(6.1)	(7.6)
Net cash (used in) provided by financing activities	(1.5)	5.3
Effect of exchange rate changes on cash and cash equivalents	(1.3)	(9.2)
Net change in cash and cash equivalents	(21.7)	4.7
Beginning balance of cash and cash equivalents	606.9	1,073.6
Ending balance of cash and cash equivalents	585.2	1,078.3
Supplemental data:
Cash paid for interest	14.3	2.8
Cash paid for taxes	6.6	14.1
ROU assets obtained in exchange for operating lease obligations	$ 7.6	$ 7.1